Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377204 | 1.00 | ADORA2A (0.61) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL272584 | 1.00 | ADORA2A (0.61) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL271777 | 0.92 | ADORA2A (0.63) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL271079 | 0.92 | ADORA2A (0.61) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL5386813 | 0.88 | ADORA3 (0.58) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL3826172 | 0.86 | ADORA2A (0.63) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL5397271 | 0.84 | ADORA3 (0.60) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL3949601 | 0.82 | ADORA1 (0.62) | ADORA2AADORA2BADORA3ADORA1NT5E | |
| SCHEMBL3947025 | 0.82 | ADORA1 (0.62) | ADORA2AADORA2BADORA3ADORA1NT5E | |
| SCHEMBL5034539 | 0.82 | ADORA1 (0.62) | ADORA2AADORA2BADORA3ADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47351-E1 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| EP-1708721-B1 | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS | GILEAD SCIENCES INC (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2366396-B1 | Myocardial perfusion imaging using adenosine receptor agonists | GILEAD SCIENCES INC (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2056834-B1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | GILEAD SCIENCES INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2366396-A1 | Myocardial perfusion imaging using adenosine receptor agonists | Gilead Palo Alto, Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| US-7683037-B2 | A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; | GILEAD PALO ALTO, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2099360-A2 | MYOCARDIAL PERFUSION IMAGING | CV Therapeutics Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008086096-A2 | MYOCARDIAL PERFUSION IMAGING | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1708721-A1 | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005082379-A1 | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1524984-A1 | MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20040064039-A1 | Myocardial perfusion imaging method | CV THERAPEUTICS | 2004-04-01 | — | — | US | disclosed |
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004011010-A1 | MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-6403567-B1 | N-pyrazole A2A adenosine receptor agonists | CV THERAPEUTICS, INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 5/4885ADORA3 2/4885 |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | ADORA2A, ADORA3, ADRB3 | ADORA2A 1/4885ADORA2B 5/4885ADORA3 2/4885 |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | ADORA2A, FABP3, ADORA3 | ADORA2A 1/4885ADORA2B 9/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.